We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01131676
Recruitment Status : Completed
First Posted : May 27, 2010
Results First Posted : May 16, 2016
Last Update Posted : May 16, 2016
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: BI 10773 low dose Drug: Placebo BI 10773 high dose Drug: BI 10773 high dose Drug: Placebo BI 10773 low dose Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7064 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
Study Start Date : July 2010
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: BI 10773 low dose
BI 10773 tablets once daily
 Drug: BI 10773 low dose
BI 10773 tablets once daily

Drug: Placebo BI 10773 high dose
Placebo tablets identical to BI 10773
Experimental: BI 10773 high dose
BI 10773 tablets once daily
 Drug: BI 10773 high dose
BI 10773 tablets once daily

Drug: Placebo BI 10773 low dose
Placebo tablets identical to BI 10773
Placebo Comparator: Placebo
Placebo tablets matching BI 10773
 Drug: Placebo BI 10773 high dose
Placebo tablets identical to BI 10773

Drug: Placebo BI 10773 low dose
Placebo tablets identical to BI 10773


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

    Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), and non-fatal stroke.

    Percentage of patients with the event are presented.



Secondary Outcome Measures :
  1. Percentage of Participants With the Composite of All Events Adjudicated (4-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), Non-fatal Stroke and Hospitalization for Unstable Angina Pectoris [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

    The composite of all events adjudicated (4-point MACE): cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction (excluding silent MI), non-fatal stroke and hospitalization for unstable angina pectoris.This is a key secondary endpoint of the trial.

    Percentage of patients with the event are presented.


  2. Percentage of Participants With Silent MI [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

    Silent MI; defined as presence in the ECG of:

    • Any Q-wave in leads V2-V3 ≥0.02 seconds or QS complex in leads V2 and V3
    • Q-wave ≥0.03 seconds and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF)
    • R-wave ≥0.04 seconds in V1-V2 and R/S ≥1 with a concordant positive T-wave in the absence of a conduction defect.

    It was also required that there had been no adjudicated and confirmed event of either acute MI, hospitalisation for unstable angina, coronary revascularisation procedures or stent thrombosis following randomisation up to and including the date of the specified ECG measurement.

    Percentage of patients with the event are presented.


  3. Percentage of Participants With Heart Failure Requiring Hospitalisation (Adjudicated) [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]
    Heart failure requiring hospitalisation (adjudicated). Percentage of patients with the event are presented.

  4. Percentage of Participants With New Onset Albuminuria [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

    New onset albuminuria defined as urine albumin / creatinine ratio (UACR) ≥30 mg/g.

    Percentage of patients with the event are presented.


  5. Percentage of Participants With New Onset Macroalbuminuria [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]
    New onset macroalbuminuria defined as UACR >300 mg/g. Percentage of patients with the event are presented.

  6. Percentage of Participants With the Composite Microvascular Outcome [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

    Composite microvascular outcome defined as:

    • Initiation of retinal photocoagulation
    • Vitreous haemorrhage
    • Diabetes-related blindness, or

    • New or worsening nephropathy defined as:

      • New onset of macroalbuminuria; or
      • Doubling of serum creatinine level accompanied by an eGFR (based on modification of diet in renal disease (MDRD) formula) ≤45 mL/min/1.73m2; or
      • Initiation of continuous renal replacement therapy, or
      • Death due to renal disease. Percentage of patients with the event are presented.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Diagnosis of type 2 diabetes mellitus prior to informed consent
  2. Male or female patients on diet and exercise regimen who are drug naive or pre treated with any background therapy. Antidiabetic therapy has to be unchanged for 12 weeks prior to randomization.
  3. Glycosylated haemoglobin (HbA1c) of >= 7.0% and <=10% for patients on background therapy or HbA1c >= 7.0% and <= 9.0% for drug naive patients
  4. Age >= 18 years
  5. Body Mass index <= 45 at Visit 1
  6. Signed and dated informed consent
  7. High cardiovascular risk

Exclusion criteria:

  1. Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day)
  2. Indication of liver disease, defined by serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase ALT or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at screening and/or run in.
  3. Planned cardiac surgery or angioplasty within 3 months
  4. Impaired renal function, defined as Glomerular Filtration Rate <30 ml/min (severe renal impairment, Modification of Diet in Renal Disease formula) during screening or run in.
  5. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption
  6. Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia)
  7. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years
  8. Contraindications to background therapy according to the local label
  9. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight
  10. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except type 2 diabetes mellitus

  11. Pre-menopausal women (last menstruation <+ 1 year prior to informed consent) who:

    • are nursing or pregnant or
    • are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable or injectable contraceptives, sexual abstinence, double barrier method and vasectomised partner
  12. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake
  13. Participation in another trial with an investigational drug within 30 days prior to informed consent
  14. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial
  15. Acute coronary syndrome, stroke or TIA within 2 months prior to informed consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01131676


Locations
Show Show 615 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01131676    
Other Study ID Numbers: 1245.25
2009-016178-33 ( EudraCT Number: EudraCT )
First Posted: May 27, 2010    Key Record Dates
Results First Posted: May 16, 2016
Last Update Posted: May 16, 2016
Last Verified: April 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
 Empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs